Merck & Co., Inc. vs Suncor Energy Inc. — how do they compare? Merck & Co., Inc. trades at $142.38 (market cap $352.29B), while Suncor Energy Inc. trades at $70.84 (market cap $80.03B). The key difference: Merck & Co., Inc. is far larger — about 4.4× Suncor Energy Inc.'s market cap, and Suncor Energy Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Suncor Energy Inc. for 57 Days on average.
| MRK | SU | |
|---|---|---|
Market Cap | $352.29B | $80.03B |
Volume | 6,348,796 | 2,907,827 |
Sector | Health | Energy |
52-Week High | $156.43 | $71.87 |
52-Week Low | $82.49 | $38.17 |
Typical Hold Time | 98 Days | 57 Days |
Enterprise Value | $399.05B | $86.58B |
Dividend Yield | 2.38% | 2.49% |
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.40, up 0.33% on the day, with a bearish technical signal but strong analyst support. The company reported revenue of $65.0B in 2025 with a net income margin of 28.07%, though 2026 projections show a sharp decline to 4.76%. Recent acquisition activity includes the tender offer for Terns Pharmaceuticals to bolster its oncology pipeline, while cash flow trends indicate significant investing outflows in 2026.
The outlook is mixed: robust fundamentals and a consensus price target of $159.59 suggest upside, but high valuation ratios (P/E 114.23) and projected earnings volatility pose risks. Investors should weigh strong institutional buying against technical weakness and competitive pressures in the pharma sector.
Suncor Energy (SU) trades at $70.91, up 3.94% today, reflecting strong momentum near recent highs. The stock exhibits a bullish technical trend with support at $68 and resistance at $69. Fundamentally, SU maintains solid profitability with a 14.7% net income margin and attractive valuation at a P/E of 12.98. Recent Q2 2026 earnings beat expectations, and the company announced a $0.60 dividend for H2-2026. Cash flow remains robust, supporting shareholder returns via buybacks.
The outlook for SU is positive, driven by strong cash generation, debt reduction, and strategic asset sales. Investment appeal lies in its integrated model, shareholder returns, and exposure to global energy markets. Key risks include commodity price volatility, operational disruptions from weather, and execution of leadership transition. Analyst consensus is strongly bullish with 74% buy ratings, signaling confidence in continued performance.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →